What is it about?
We evaluated the therapeutical strategies for Parkinson's disease used in our neurology clinics to define the role of monoamine oxidase B inhibitors. From the 2194 reports we found that 535 (24,3%) patients recevied selegiline or rasagiline in monotherapy or combinations.
Featured Image
Why is it important?
The treating physicians should utilise more confidently the available therapeutical combinations.
Perspectives
It was interesting to me to see results from this huge database related to our everyday practice with Parkinson's disease.
Szabolcs Szatmari
University of Medicine and Pharmacy Tirgu Mures
Read the Original
This page is a summary of: A szelektív monoaminoxidáz-B-gátlók helye a Parkinson-kór kezelési stratégiájában a marosvásárhelyi ideggyógyászati klinikák gyakorlatában, Orvosi Hetilap, December 2017, Akademiai Kiado,
DOI: 10.1556/650.2017.30914.
You can read the full text:
Contributors
The following have contributed to this page
